EE+ POEM Archive
In patients with T2DM and high-risk chronic renal disease, semaglutide reduces cardiovascular, renal, and mortality outcomes (FLOW)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "In Patients With T2DM and High-risk Chronic Renal Disease, Semaglutide Reduces Cardiovascular, Renal, and Mortality Outcomes (FLOW)." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377195/all/In_patients_with_T2DM_and_high_risk_chronic_renal_disease__semaglutide_reduces_cardiovascular__renal__and_mortality_outcomes__FLOW_.
In patients with T2DM and high-risk chronic renal disease, semaglutide reduces cardiovascular, renal, and mortality outcomes (FLOW). In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377195/all/In_patients_with_T2DM_and_high_risk_chronic_renal_disease__semaglutide_reduces_cardiovascular__renal__and_mortality_outcomes__FLOW_. Accessed September 18, 2024.
In patients with T2DM and high-risk chronic renal disease, semaglutide reduces cardiovascular, renal, and mortality outcomes (FLOW). (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377195/all/In_patients_with_T2DM_and_high_risk_chronic_renal_disease__semaglutide_reduces_cardiovascular__renal__and_mortality_outcomes__FLOW_
In Patients With T2DM and High-risk Chronic Renal Disease, Semaglutide Reduces Cardiovascular, Renal, and Mortality Outcomes (FLOW) [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 September 18]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377195/all/In_patients_with_T2DM_and_high_risk_chronic_renal_disease__semaglutide_reduces_cardiovascular__renal__and_mortality_outcomes__FLOW_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - In patients with T2DM and high-risk chronic renal disease, semaglutide reduces cardiovascular, renal, and mortality outcomes (FLOW)
ID - 3377195
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377195/all/In_patients_with_T2DM_and_high_risk_chronic_renal_disease__semaglutide_reduces_cardiovascular__renal__and_mortality_outcomes__FLOW_
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
